Long non‑coding RNA TP73‑AS1 accelerates the progression and cisplatin resistance of non‑small cell lung cancer by upregulating the expression of TRIM29 via competitively targeting microRNA‑34a‑5p

Mol Med Rep. 2020 Nov;22(5):3822-3832. doi: 10.3892/mmr.2020.11473. Epub 2020 Sep 1.

Abstract

Non‑small cell lung cancer (NSCLC) is a leading subtype of lung cancer, with high mortality rates. Recently, long non‑coding RNAs (lncRNAs) have been associated with NSCLC. The present study aimed to examine the role of the TP73 antisense RNA 1 (TP73‑AS1) lncRNA in NSCLC. TP73‑AS1 and microRNA(miR)‑34a‑5p expression levels were measured using reverse transcription‑quantitative PCR (RT‑qPCR) and chromogenic in situ hybridization (CISH). Cell proliferation, apoptosis, migration and invasion was determined using Cell Counting Kit‑8 (CCK‑8), flow cytometry, Transwell and Matrigel assays, respectively. The median inhibitory concentration (IC50) value of cisplatin (cis‑diamminedichloroplatinum; DDP) was assessed using a CCK‑8 assay. The interaction between miR‑34a‑5p and TP73‑AS1 or tripartite motif‑containing 29 (TRIM29) was predicted using microRNA.org and Starbase, then verified using a dual‑luciferase reporter assay. The expression of TRIM29 was quantified at the mRNA and protein level using RT‑qPCR and western blot analysis, respectively. TP73‑AS1 was significantly upregulated, while miR‑34a‑5p was downregulated in NSCLC tissues and cells. Functionally, TP73‑AS1 knockdown inhibited proliferation, migration, invasion and DDP resistance, whilst inducing apoptosis in NSCLC cells. miR‑34a‑5p was identified as a target for TP73‑AS1, and its inhibition reversed the effects of TP73‑AS1 knockdown on NSCLC cells. In addition, TRIM29 was targeted by miR‑34a‑5p, and its overexpression reversed the effects of miR‑34a‑5p. Moreover, TP73‑AS1 acted as a molecular sponge for miR‑34a‑5p, increasing the expression of TRIM29. In conclusion, TP73‑AS1 contributed to proliferation, migration and DDP resistance but inhibited apoptosis of NSCLC cells by upregulating TRIM29 and sponging miR‑34a‑5p.

MeSH terms

  • Carcinoma, Non-Small-Cell Lung / drug therapy
  • Carcinoma, Non-Small-Cell Lung / genetics*
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Cell Line, Tumor
  • Cell Movement
  • Cell Proliferation
  • Cell Survival
  • Cisplatin / pharmacology*
  • DNA-Binding Proteins / genetics*
  • Disease Progression
  • Drug Resistance, Neoplasm*
  • Female
  • Gene Expression Regulation, Neoplastic
  • Humans
  • Lung Neoplasms / drug therapy
  • Lung Neoplasms / genetics*
  • Lung Neoplasms / pathology
  • Male
  • MicroRNAs / genetics*
  • Neoplasm Staging
  • Prognosis
  • RNA, Long Noncoding / genetics*
  • Survival Analysis
  • Transcription Factors / genetics*
  • Up-Regulation

Substances

  • DNA-Binding Proteins
  • MIRN34 microRNA, human
  • MicroRNAs
  • RNA, Long Noncoding
  • TRIM29 protein, human
  • Transcription Factors
  • long non-coding RNA KIAA0495, human
  • Cisplatin